Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.